Microenvironmental Influences that Drive Progression from Benign Breast Disease to Invasive Breast Cancer

Invasive breast cancer represents the endpoint of a developmental process that originates in the terminal duct lobular units and is believed to progress through stages of increasing proliferation, atypical hyperplasia, and carcinoma in situ before the cancer acquires invasive and metastatic capabilities. By comparison with invasive breast cancer, which has been studied extensively, the preceding stages of benign breast disease are more poorly understood. Much less is known about the molecular changes underlying benign breast disease development and progression, as well as the transition from in situ into invasive disease. Even less focus has been given to the specific role of stroma in this progression. The reasons for lack of knowledge about these lesions often come from their small size and limited sample availability. More challenges are posed by limitations of the models used to investigate the lesions preceding invasive breast cancer. However, recent studies have identified alterations in stromal cell function that may be critical for disease progression from benign disease to invasive cancer: key functions of myoepithelial cells that maintain tissue structure are lost, while tissue fibroblasts become activated to produce proteases that degrade the extracellular matrix and trigger the invasive cellular phenotype. Gene expression profiling of stromal alterations associated with disease progression has also identified key transcriptional changes that occur early in disease development. In this review, we will summarize recent studies showing how stromal factors can facilitate progression of ductal carcinoma in situ to invasive disease. We also suggest approaches to identify processes that control earlier stages of disease progression.

[1]  H M Jensen,et al.  On the origin and progression of ductal carcinoma in the human breast. , 1973, Journal of the National Cancer Institute.

[2]  H M Jensen,et al.  An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. , 1975, Journal of the National Cancer Institute.

[3]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[4]  Jose Russo,et al.  Human Breast Epithelial Cell Line, MCF-10 Isolation and Characterization of a Spontaneously Immortalized , 2006 .

[5]  S J London,et al.  A prospective study of benign breast disease and the risk of breast cancer. , 1992, JAMA.

[6]  F. Miller,et al.  Xenograft model of progressive human proliferative breast disease. , 1993, Journal of the National Cancer Institute.

[7]  F. Miller,et al.  The MCF10 family of spontaneously immortalized human breast epithelial cell lines: models of neoplastic progression. , 1993, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[8]  Anthony J. Guidi,et al.  Microvessel density and distribution in ductal carcinoma in situ of the breast. , 1994, Journal of the National Cancer Institute.

[9]  S. Kamel,et al.  Identification of a chemoprevention cohort from a population of women at high risk for breast cancer , 1996, Journal of cellular biochemistry. Supplement.

[10]  S. Barsky,et al.  The myoepithelial defense: a host defense against cancer. , 1997, Medical hypotheses.

[11]  Z. Shao,et al.  The human myoepithelial cell is a natural tumor suppressor. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  P. O’Connell,et al.  Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. , 1998, Journal of the National Cancer Institute.

[13]  A. Gown,et al.  Myoepithelial cells and basal lamina in poorly differentiated in situ duct carcinoma of the breast , 1999, Virchows Archiv.

[14]  U. Sauer,et al.  Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas. , 1999, Anticancer research.

[15]  F. Miller,et al.  MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. , 2000, Journal of the National Cancer Institute.

[16]  P. Hein,et al.  Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium , 2000, Breast Cancer Research.

[17]  S. Fuqua,et al.  Histological and biological evolution of human premalignant breast disease. , 2001, Endocrine-related cancer.

[18]  Mina J Bissell,et al.  Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. , 2010, Journal of cell science.

[19]  R. Salunga,et al.  Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  L. Kiemeney,et al.  High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Hudis,et al.  Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations , 2003, Cancer.

[22]  F. Miller,et al.  Progression of Premalignant MCF10AT Generates Heterogeneous Malignant Variants with Characteristic Histologic Types and Immunohistochemical Markers , 2000, Breast Cancer Research and Treatment.

[23]  Rameen Beroukhim,et al.  Molecular characterization of the tumor microenvironment in breast cancer. , 2004, Cancer cell.

[24]  Fred R. Miller,et al.  Malignant MCF10CA1 Cell Lines Derived from Premalignant Human Breast Epithelial MCF10AT Cells , 2004, Breast Cancer Research and Treatment.

[25]  R. Weinberg,et al.  Reconstruction of functionally normal and malignant human breast tissues in mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Heffelfinger,et al.  Endometase/Matrilysin-2 in Human Breast Ductal Carcinoma in Situ and Its Inhibition by Tissue Inhibitors of Metalloproteinases-2 and -4 , 2004, Cancer Research.

[27]  F. Miller Xenograft Models of Premalignant Breast Disease , 2000, Journal of Mammary Gland Biology and Neoplasia.

[28]  P. Gattuso,et al.  Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes. , 2005, Journal of the American College of Surgeons.

[29]  R. Mansel,et al.  Benign breast disorders. , 2005, The New England journal of medicine.

[30]  Tina Hernandez-Boussard,et al.  Determination of Stromal Signatures in Breast Carcinoma , 2005, PLoS biology.

[31]  D. Axelrod,et al.  Evaluation of pathways for progression of heterogeneous breast tumors. , 2005, Journal of theoretical biology.

[32]  D. Proia,et al.  Stroma: Tumor Agonist or Antagonist , 2005, Cell cycle.

[33]  Kornelia Polyak,et al.  Do Myoepithelial Cells Hold the Key for Breast Tumor Progression? , 2005, Journal of Mammary Gland Biology and Neoplasia.

[34]  Jun Yao,et al.  Distinct epigenetic changes in the stromal cells of breast cancers , 2005, Nature Genetics.

[35]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[36]  Mina J Bissell,et al.  Myoepithelial cells: good fences make good neighbors , 2005, Breast Cancer Research.

[37]  Charlotte Kuperwasser,et al.  A mouse model of human breast cancer metastasis to human bone. , 2005, Cancer research.

[38]  R. Elledge,et al.  Premalignant and In Situ Breast Disease: Biology and Clinical Implications , 2005, Annals of Internal Medicine.

[39]  A. Sahin,et al.  Benign breast diseases: classification, diagnosis, and management. , 2006, The oncologist.

[40]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[41]  Greg Finak,et al.  Gene expression signatures of morphologically normal breast tissue identify basal-like tumors , 2006, Breast Cancer Research.

[42]  Ferdinando Mannello,et al.  Benign breast diseases: classification, diagnosis, and management. , 2006, The oncologist.

[43]  Kay Nieselt,et al.  Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. , 2006, Cancer research.

[44]  M. J. van de Vijver,et al.  Classification of ductal carcinoma in situ by gene expression profiling , 2006, Breast Cancer Research.

[45]  Martin Widschwendter,et al.  Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. , 2006, Cancer research.

[46]  K. Mokbel,et al.  The role of cyclooxygenase-2 in breast cancer: review , 2008, Breast Cancer Research and Treatment.

[47]  R. Vierkant,et al.  Stratification of breast cancer risk in women with atypia: a Mayo cohort study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  D. Radisky,et al.  Stromal induction of breast cancer: Inflammation and invasion , 2007, Reviews in Endocrine and Metabolic Disorders.

[49]  Charles M. Perou,et al.  Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution , 2008, Clinical Cancer Research.

[50]  Jun Yao,et al.  Epithelial and Stromal Cathepsin K and CXCL14 Expression in Breast Tumor Progression , 2008, Clinical Cancer Research.

[51]  Jun Yao,et al.  Regulation of in situ to invasive breast carcinoma transition. , 2008, Cancer cell.

[52]  H. Kuerer,et al.  The molecular journey from ductal carcinoma in situ to invasive breast cancer , 2008, Cancer.

[53]  Xiao-Jun Ma,et al.  Gene expression profiling of the tumor microenvironment during breast cancer progression , 2009, Breast Cancer Research.

[54]  Andrew H. Beck,et al.  The fibromatosis signature defines a robust stromal response in breast carcinoma , 2008, Laboratory Investigation.

[55]  T. Sørlie,et al.  Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome , 2008, The Journal of pathology.

[56]  H. Brentani,et al.  Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma , 2008, Breast Cancer Research.

[57]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[58]  S. Schnitt The transition from ductal carcinoma in situ to invasive breast cancer: the other side of the coin , 2009, Breast Cancer Research.

[59]  Andrew H. Beck,et al.  Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ , 2010, Breast Cancer Research and Treatment.

[60]  S. Schnitt,et al.  Phenotypic Alterations in Ductal Carcinoma In Situ-associated Myoepithelial Cells: Biologic and Diagnostic Implications , 2009, The American journal of surgical pathology.

[61]  Andrew H. Beck,et al.  The Macrophage Colony-Stimulating Factor 1 Response Signature in Breast Carcinoma , 2009, Clinical Cancer Research.

[62]  R. DePinho,et al.  Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice , 2009, Proceedings of the National Academy of Sciences.

[63]  A. Howell,et al.  Breast tumour stroma is a prognostic indicator and target for therapy , 2009, Breast Cancer Research.

[64]  Robert D Cardiff,et al.  Ductal carcinoma in situ: state of the science and roadmap to advance the field. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  K. Polyak,et al.  Role of COX-2 in epithelial–stromal cell interactions and progression of ductal carcinoma in situ of the breast , 2009, Proceedings of the National Academy of Sciences.

[66]  G. Colditz,et al.  Evaluation of a breast cancer risk prediction model expanded to include category of prior benign breast disease lesion , 2010, Cancer.

[67]  Jorge S. Reis-Filho,et al.  Histological types of breast cancer: How special are they? , 2010, Molecular oncology.

[68]  D. Radisky,et al.  Matrix Metalloproteinase-Induced Epithelial-Mesenchymal Transition in Breast Cancer , 2010, Journal of Mammary Gland Biology and Neoplasia.

[69]  J. Reis-Filho,et al.  Breast cancer precursors revisited: molecular features and progression pathways , 2010, Histopathology.

[70]  C. Gialeli,et al.  Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting , 2011, The FEBS journal.

[71]  D. Sgroi,et al.  The molecular pathology of breast cancer progression , 2011, The Journal of pathology.

[72]  Ingebrigt Sylte,et al.  Regulation of matrix metalloproteinase activity in health and disease , 2011, The FEBS journal.